This article was originally published in The Tan Sheet
Executive SummaryA collaboration between Vectura and Unilever has resulted in the formation of the new PharmaKodex specialty pharmaceutical company, the firms announce May 15. The new entity will employ a range of proprietary oral, transdermal and enabling technologies from both companies to develop a pipeline of Rx and OTC products. Currently, the pipeline contains six nonprescription drugs in development. PharmaKodex plans to repurpose "existing drugs for new indications or combinations, or to provide an improved route of administration," according to the release. Vectura and Unilever both will "retain a significant shareholding in PharmaKodex," the firms state...
You may also be interested in...
Eighteen years of free trade threatens to crash, as a result of the stalemate in the market access agreement between Switzerland and the EU. Industry association Swiss Medtech is advising local medtech manufacturers to find notified bodies and authorized representatives based in the EU. However, local company SQS remains confident of its ongoing notified body role.
With $1.3bn invested in over 200 high-tech start-ups, OurCrowd is now sharpening its focus on medtech. Medtech Insight spoke to founder Jon Medved to find out more.
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.